Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Cidara Therapeutics
NasdaqCM:CDTX Community
Create a narrative
Cidara Therapeutics
Undervalued
Overvalued
Cidara Therapeutics
BI
birdflustocks
Community Contributor
Cidara Therapeutics: The underestimated potential of CD388
Summary CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.
View narrative
US$100.00
FV
78.0% undervalued
intrinsic discount
83.73%
Revenue growth p.a.
Set as Fair Value
6
users have liked this narrative
0
users have commented on this narrative
32
users have followed this narrative
30 days ago
author updated this narrative
Your Valuation for
CDTX
Cidara Therapeutics
Your Fair Value
US$
Current Price
US$21.99
74.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-139m
242m
2015
2018
2021
2024
2025
2027
2030
Revenue US$242.4m
Earnings US$48.9m
Advanced
Set as Fair Value